Literature DB >> 25487009

Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates.

Samantha M Gromek, Marcy J Balunas1.   

Abstract

Antibody-drug conjugates (ADCs) are an emerging area of study within medicinal chemistry and are thought of as sophisticated drug delivery systems due to their specificity to a disease-targeted antigen. ADCs have been actively utilized as therapeutics for hematological and solid tumor cancers due to their capability to deliver a cytotoxic compound to a specific cancer cell without affecting normal cells. An antibody drug conjugate has three major constituents: a monoclonal antibody (mAb), a chemical linker, and a potent cytotoxic payload. There has been a continuing effort to optimize antibody-drug conjugates, with the primary focus of design and development directed at either the mAb or the chemical linker, with little effort devoted to the optimization of payload compounds. In fact, among the 114 ongoing or recently completed clinical trials, there is generally a lack of diversity in the cytotoxic payloads that are utilized, with only seven payload compounds reported (four additional trials are ongoing with structures that have not been reported). Six of these seven payload compounds are derived from natural product sources, highlighting the importance of natural products as cytotoxic payloads for ADC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25487009     DOI: 10.2174/1568026615666141208111253

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  4 in total

1.  Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Authors:  Leanna R Staben; Stefan G Koenig; Sophie M Lehar; Richard Vandlen; Donglu Zhang; Josefa Chuh; Shang-Fan Yu; Carl Ng; Jun Guo; Yanzhou Liu; Aimee Fourie-O'Donohue; MaryAnn Go; Xin Linghu; Nathaniel L Segraves; Tao Wang; Jinhua Chen; BinQing Wei; Gail D Lewis Phillips; Keyang Xu; Katherine R Kozak; Sanjeev Mariathasan; John A Flygare; Thomas H Pillow
Journal:  Nat Chem       Date:  2016-10-17       Impact factor: 24.427

Review 2.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 3.  Antibody-drug conjugates as novel anti-cancer chemotherapeutics.

Authors:  Christina Peters; Stuart Brown
Journal:  Biosci Rep       Date:  2015-06-12       Impact factor: 3.840

Review 4.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.